808 related articles for article (PubMed ID: 27662300)
1. An Intranasal Formulation of Erythropoietin (Neuro-EPO) Prevents Memory Deficits and Amyloid Toxicity in the APPSwe Transgenic Mouse Model of Alzheimer's Disease.
Rodríguez Cruz Y; Strehaiano M; Rodríguez Obaya T; García Rodríguez JC; Maurice T
J Alzheimers Dis; 2017; 55(1):231-248. PubMed ID: 27662300
[TBL] [Abstract][Full Text] [Related]
2. Intranasal formulation of erythropoietin (EPO) showed potent protective activity against amyloid toxicity in the Aβ₂₅₋₃₅ non-transgenic mouse model of Alzheimer's disease.
Maurice T; Mustafa MH; Desrumaux C; Keller E; Naert G; de la C García-Barceló M; Rodríguez Cruz Y; Garcia Rodríguez JC
J Psychopharmacol; 2013 Nov; 27(11):1044-57. PubMed ID: 23813967
[TBL] [Abstract][Full Text] [Related]
3. S14G-humanin improves cognitive deficits and reduces amyloid pathology in the middle-aged APPswe/PS1dE9 mice.
Zhang W; Zhang W; Li Z; Hao J; Zhang Z; Liu L; Mao N; Miao J; Zhang L
Pharmacol Biochem Behav; 2012 Jan; 100(3):361-9. PubMed ID: 21993310
[TBL] [Abstract][Full Text] [Related]
4. Soluble Aβ levels correlate with cognitive deficits in the 12-month-old APPswe/PS1dE9 mouse model of Alzheimer's disease.
Zhang W; Hao J; Liu R; Zhang Z; Lei G; Su C; Miao J; Li Z
Behav Brain Res; 2011 Sep; 222(2):342-50. PubMed ID: 21513747
[TBL] [Abstract][Full Text] [Related]
5. CEPO-Fc (An EPO Derivative) Protects Hippocampus Against Aβ-induced Memory Deterioration: A Behavioral and Molecular Study in a Rat Model of Aβ Toxicity.
Hooshmandi E; Motamedi F; Moosavi M; Katinger H; Zakeri Z; Zaringhalam J; Maghsoudi A; Ghasemi R; Maghsoudi N
Neuroscience; 2018 Sep; 388():405-417. PubMed ID: 30102955
[TBL] [Abstract][Full Text] [Related]
6. Oral administration of methysticin improves cognitive deficits in a mouse model of Alzheimer's disease.
Fragoulis A; Siegl S; Fendt M; Jansen S; Soppa U; Brandenburg LO; Pufe T; Weis J; Wruck CJ
Redox Biol; 2017 Aug; 12():843-853. PubMed ID: 28448946
[TBL] [Abstract][Full Text] [Related]
7. Comparative studies using the Morris water maze to assess spatial memory deficits in two transgenic mouse models of Alzheimer's disease.
Edwards SR; Hamlin AS; Marks N; Coulson EJ; Smith MT
Clin Exp Pharmacol Physiol; 2014 Oct; 41(10):798-806. PubMed ID: 25115283
[TBL] [Abstract][Full Text] [Related]
8. (-)-Epigallocatechin-3-gallate ameliorates memory impairment and rescues the abnormal synaptic protein levels in the frontal cortex and hippocampus in a mouse model of Alzheimer's disease.
Guo Y; Zhao Y; Nan Y; Wang X; Chen Y; Wang S
Neuroreport; 2017 Jul; 28(10):590-597. PubMed ID: 28520620
[TBL] [Abstract][Full Text] [Related]
9. A modified formulation of Chinese traditional medicine improves memory impairment and reduces Aβ level in the Tg-APPswe/PS1dE9 mouse model of Alzheimer's disease.
Jeon S; Bose S; Hur J; Jun K; Kim YK; Cho KS; Koo BS
J Ethnopharmacol; 2011 Sep; 137(1):783-9. PubMed ID: 21762767
[TBL] [Abstract][Full Text] [Related]
10. Deletion of the type-1 interferon receptor in APPSWE/PS1ΔE9 mice preserves cognitive function and alters glial phenotype.
Minter MR; Moore Z; Zhang M; Brody KM; Jones NC; Shultz SR; Taylor JM; Crack PJ
Acta Neuropathol Commun; 2016 Jul; 4(1):72. PubMed ID: 27400725
[TBL] [Abstract][Full Text] [Related]
11. Protective effects of Alpinae Oxyphyllae Fructus extracts on lipopolysaccharide-induced animal model of Alzheimer's disease.
Wang Y; Wang M; Fan K; Li T; Yan T; Wu B; Bi K; Jia Y
J Ethnopharmacol; 2018 May; 217():98-106. PubMed ID: 29447949
[TBL] [Abstract][Full Text] [Related]
12. Brain Penetrating Bifunctional Erythropoietin-Transferrin Receptor Antibody Fusion Protein for Alzheimer's Disease.
Chang R; Al Maghribi A; Vanderpoel V; Vasilevko V; Cribbs DH; Boado R; Pardridge WM; Sumbria RK
Mol Pharm; 2018 Nov; 15(11):4963-4973. PubMed ID: 30252487
[TBL] [Abstract][Full Text] [Related]
13. The flavonoid baicalein rescues synaptic plasticity and memory deficits in a mouse model of Alzheimer's disease.
Gu XH; Xu LJ; Liu ZQ; Wei B; Yang YJ; Xu GG; Yin XP; Wang W
Behav Brain Res; 2016 Sep; 311():309-321. PubMed ID: 27233830
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of nose-to-brain delivery of basic fibroblast growth factor for improving rat memory impairments induced by co-injection of β-amyloid and ibotenic acid into the bilateral hippocampus.
Feng C; Zhang C; Shao X; Liu Q; Qian Y; Feng L; Chen J; Zha Y; Zhang Q; Jiang X
Int J Pharm; 2012 Feb; 423(2):226-34. PubMed ID: 22193058
[TBL] [Abstract][Full Text] [Related]
15. Neuropeptide Y (NPY) prevents depressive-like behavior, spatial memory deficits and oxidative stress following amyloid-β (Aβ(1-40)) administration in mice.
dos Santos VV; Santos DB; Lach G; Rodrigues AL; Farina M; De Lima TC; Prediger RD
Behav Brain Res; 2013 May; 244():107-15. PubMed ID: 23396168
[TBL] [Abstract][Full Text] [Related]
16. CART modulates beta-amyloid metabolism-associated enzymes and attenuates memory deficits in APP/PS1 mice.
Yin K; Jin J; Zhu X; Yu L; Wang S; Qian L; Han L; Xu Y
Neurol Res; 2017 Oct; 39(10):885-894. PubMed ID: 28743230
[TBL] [Abstract][Full Text] [Related]
17. Improvement of memory deficits in the rat model of Alzheimer's disease by erythropoietin-loaded solid lipid nanoparticles.
Dara T; Vatanara A; Sharifzadeh M; Khani S; Vakilinezhad MA; Vakhshiteh F; Nabi Meybodi M; Sadegh Malvajerd S; Hassani S; Mosaddegh MH
Neurobiol Learn Mem; 2019 Dec; 166():107082. PubMed ID: 31493483
[TBL] [Abstract][Full Text] [Related]
18. Chronic phosphodiesterase type 2 inhibition improves memory in the APPswe/PS1dE9 mouse model of Alzheimer's disease.
Sierksma AS; Rutten K; Sydlik S; Rostamian S; Steinbusch HW; van den Hove DL; Prickaerts J
Neuropharmacology; 2013 Jan; 64():124-36. PubMed ID: 22771768
[TBL] [Abstract][Full Text] [Related]
19. SEN1500, a novel oral amyloid-β aggregation inhibitor, attenuates brain pathology in a mouse model of Alzheimer's disease.
Brunner D; Flunkert S; Neddens J; Duller S; Scopes DIC; Treherne JM; Hutter-Paier B
Neurosci Lett; 2017 Nov; 660():96-102. PubMed ID: 28917978
[TBL] [Abstract][Full Text] [Related]
20. Citalopram restores short-term memory deficit and non-cognitive behaviors in APP/PS1 mice while halting the advance of Alzheimer's disease-like pathology.
Zhang Q; Yang C; Liu T; Liu L; Li F; Cai Y; Lv K; Li X; Gao J; Sun D; Xu H; Yang Q; Fan X
Neuropharmacology; 2018 Mar; 131():475-486. PubMed ID: 29241655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
